TA-35 closes 0.29% higher at 4,048.94 points
Published on 11/03/2026 at 22:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTA-35 recovers after volatile session
- The TA-35 closed 0.29% higher at 4,048.94 points on November 3, 2026.
- Teva and banking stocks supported the index, while NICE, ICL and Next Vision fell sharply.
- Market breadth remained weak, with 311 declining stocks against 145 advancers on the Tel Aviv Stock Exchange.
The TA-35 closed higher on Tuesday, November 3, 2026, as gains in pharmaceutical and banking shares offset heavy losses in several technology and chemical companies. The benchmark ended at 4,048.94 points, up 0.29% from the previous session's close of 4,037.36. The closing level and the session's main movers were reported by Globes.
Teva and banks provide support
Teva Pharmaceutical Industries was the strongest TA-35 constituent, rising 3.75% after the company reported strong third-quarter results. Ormat Technologies gained 2.75%, while NewMed Energy advanced 2.58%. Bank Hapoalim, Bank Leumi and Israel Discount Bank also moved higher, gaining 2.34%, 2.03% and 1.75%, respectively.
Teva's performance followed quarterly results that included stronger-than-expected adjusted earnings and an improved 2026 revenue outlook, according to reporting on the company's results. The market response therefore reflected company-specific news rather than a broad-based advance across the index.
Technology losses limit the advance
NICE was the weakest TA-35 component, falling 7.07% after announcing plans to eliminate 5% of its workforce. Next Vision declined 4.51%, while ICL lost 4.06%. Enlight Renewable Energy and Nova also finished lower after their quarterly updates. The contrast between Teva's gain and NICE's decline left the index higher despite substantial pressure among technology-related shares.
Market breadth underscored the narrow character of the recovery. Investing.com reported 311 declining stocks on the Tel Aviv Stock Exchange, compared with 145 rising issues and 101 unchanged. Banking, biomedicine and financials were the leading sectors at the close, while the broader TA-125 slipped 0.03%.
For investors, the session points to continued dispersion within Israeli equities. The TA-35's modest gain did not signal uniform strength: earnings momentum and guidance helped lift Teva, while restructuring concerns and company-specific results weighed on other large constituents. Further index direction will depend on whether support from banks and pharmaceuticals broadens beyond a limited group of heavyweight stocks. More coverage is available on the TA-35 topic page.
